Docstoc

UNIVERSITY OF MICHIGAN ONCOLOGIST RECEIVES BREAST

Document Sample
UNIVERSITY OF MICHIGAN ONCOLOGIST RECEIVES BREAST Powered By Docstoc
					 UNIVERSITY OF MICHIGAN ONCOLOGIST RECEIVES BREAST CANCER
 RESEARCH FOUNDATION GRANT FOR WORK WITH TUMOR MARKERS

               Funding made possible through the support of Eisai Inc.


Woodcliff Lake, NJ, October 25, 2011 – The Breast Cancer Research Foundation
(BCRF) announced today that it has awarded a research grant to Daniel F. Hayes, MD,
Director of the Breast Oncology Program at the University of Michigan Comprehensive
Cancer Center, for his work on behalf of the North American Breast Cancer Group
(NABCG). The award is funded through a sponsorship from Eisai Inc.

Each year BCRF’s Board of Scientific Advisors invites meritorious individuals and
groups to submit proposals for support of promising clinical and translational research
studies aimed at breast cancer prevention and cure.

“Eisai is honored to support continued research into breast cancer with the hope that one
day this research may improve the lives of patients with cancer,” said Dr. Takashi Owa,
chief scientific officer, Eisai Product Creation Systems and president of the Oncology
Product Creation Unit at Eisai Inc.

Dr. Hayes, a professor of internal medicine at the University of Michigan, also leads the
NABCG, which conducts prospective randomized clinical trials that have changed
practice patterns for patients with breast cancer, especially at the beginning of therapy.

“On behalf of my colleagues at NABCG, I am honored to receive this grant from The
Breast Cancer Research Foundation. We are committed through our research to improve
personalized cancer care and treatment of patients,” said Dr. Hayes. “I am grateful to
Eisai for supporting important breast cancer research studies through its generosity to
BCRF.”

The Correlative Science Committee of the NABCG studies tumor markers and the role
they play in determining a breast cancer patient’s therapy. NABCG has collected and
stored breast cancer tissue from patients who have participated in clinical trials since the
early 1990’s. The funding for this project enables use of these tissue samples for studies
of new or promising tumor markers. These studies are subject to a rigorous review
process.

About BCRF
The Breast Cancer Research Foundation® was founded in 1993 by Evelyn H. Lauder as
an independent, not-for-profit organization dedicated to funding innovative clinical and
translational research. In October 2011, BCRF is awarding $36.5 million to 186 scientists
across the United States, Canada, Latin America, Europe, the Middle East, Australia and
China. Currently, more than 90 cents of every dollar donated is directed to breast cancer
research and awareness programs. With exceptionally low administrative costs, BCRF
continues to be one of the most efficient organizations in the country and is designated an
“A+” charity by The American Institute of Philanthropy, the only cancer organization to
achieve this. For more information about BCRF, visit www.bcrfcure.org.

Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United
States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated
pharmaceutical business. Eisai’s areas of commercial focus include neurology,
gastrointestinal disorders and oncology/critical care. The company serves as the U.S.
pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc)
company that discovers, develops and markets products throughout the world.

Eisai Oncology is dedicated to discovering, developing and producing innovative
oncology therapies that may make a difference and impact the lives of patients and their
families. This passion for people is part of Eisai’s human health care (hhc) mission,
which strives for better understanding of the needs of patients and their families to
increase the benefits health care provides. Our commitment to meaningful progress in
oncology research, built on scientific expertise, is supported by a global capability to
conduct discovery and preclinical research, and develop small molecules, vaccines, and
biologic agents across various types of cancer. For more information about Eisai, please
visit www.eisai.com/US.



Media Inquiries:
Laurie Landau
Eisai Inc.
Laurie_landau@eisai.com
201-746-2510



Anna DeLuca
Breast Cancer Research Fund
Annadeluca@aol.com
646-497-2609

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:0
posted:3/24/2012
language:
pages:2
yaohongm yaohongm http://
About